GlassScriptPhysician profile
Anne V Healy
NPI 1598949935
$4,733.59
in general payments reported to CMS, 2019-2025
32 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,084 · 2020: $754 · 2021: $859 · 2022: $539 · 2023: $737 · 2024: $761.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,498.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,497.75 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $1,188.65 | 2019-2024 | Otezla, Repatha |
| Lilly USA, LLC | $542.99 | 2019-2024 | Mounjaro, Zepbound, Jardiance |
| Novo Nordisk INC | $540.19 | 2019-2024 | Wegovy, Rybelsus, Ozempic |
| Astrazeneca Pharmaceuticals LP | $466.65 | 2019-2024 | Farxiga, Airsupra, Breztri |
| Glaxosmithkline, LLC. | $381.92 | 2019-2024 | Shingrix, Arexvy, Trelegy Ellipta |
| Boehringer Ingelheim Pharmaceuticals, INC. | $252.93 | 2020-2024 | Jardiance |
| Abbvie INC. | $223.64 | 2019-2024 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $206.45 | 2019-2024 | Xifaxan, Trulance |
| Pfizer INC. | $179.84 | 2019-2024 | |
| Astellas Pharma US INC | $106.04 | 2019-2023 | Veozah |
| Dexcom, INC. | $76.39 | 2020-2024 | Dexcom G6 Transmitter |
| Daiichi Sankyo INC. | $72.62 | 2019-2022 | |
| Allergan, INC. | $50.34 | 2019-2020 | |
| Sumitomo Pharma America, INC. | $49.22 | 2023-2024 | Gemtesa |
| Merck Sharp & Dohme LLC | $43.40 | 2020-2024 | Gardasil 9, Gardasil, Capvaxive |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Kowa Pharmaceuticals America, INC. | $42.95 | 2019-2021 | |
| Mylan Specialty L.P. | $37.19 | 2021-2022 | |
| Radius Health, INC. | $32.74 | 2023 | Tymlos |
| Currax Pharmaceuticals LLC | $28.24 | 2019-2024 | Contrave |
| Grifols USA, LLC | $24.54 | 2024 | Prolastin-C Liquid |
| Abbott Laboratories | $21.57 | 2022 | |
| Dermira, INC. | $18.80 | 2020 | |
| Philips North America LLC | $18.54 | 2023 | |
| Ironwood Pharmaceuticals, INC | $17.69 | 2023 | Linzess |
| Upsher-Smith Laboratories LLC | $15.37 | 2021 | |
| Janssen Pharmaceuticals, INC | $15.36 | 2023 | Xarelto |
| Phathom Pharmaceuticals, INC. | $14.64 | 2024 | Voquezna |
| Exact Sciences Corporation | $14.14 | 2024 | Cologuard Collection Kit |
| Arbor Pharmaceuticals, INC. | $13.67 | 2019 | |
| Phadia US INC. | $13.04 | 2021 | |
| Teva Pharmaceuticals USA, INC. | $12.46 | 2020 | |
| Hikma Pharmaceuticals USA | $11.38 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Anne Healy listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.